(P091) Sarcopenia/Cachexia Is Associated With Reduced Survival and Locoregional Control in Head and Neck Cancer Patients Receiving Radiotherapy: Results From Quantitative Imaging Analysis of Lean Body Mass

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

We confirm that analysis of routine CT scans for sarcopenia can predict outcomes for HNSCC patients. Pre-RT sarcopenia is associated with more poor outcomes for nonoperated patients and post-RT sarcopenia for all HNSCC patients. Post-RT sarcopenia, as measured by routine CT, outperformed simple weight loss and BMI-derived cachexia metrics, because loss of lean muscle mass can occur independently of BMI status. These findings suggest the potential benefit for investigating intervention with aggressive nutritional and physiatric methods to prevent sarcopenia during RT and to study how these interventions might affect outcomes in nonoperated, pre-RT sarcopenia patients.

Sasikarn Chamchod, MD, Clifton D. Fuller, MD, PhD, Aaron J. Grossberg, MD, PhD, Abdallah S. Mohamed, MD, MSc, Jolien Heukelom, MD, Hillary Eichelberger, BA, BS, Michael E. Kantor, BS, Gary B. Gunn, MD, Adam S. Garden, MD, Steven J. Frank, MD, Jack Phan, MD, PhD, Beth M. Beadle, MD, PhD, Heath D. Skinner, MD, PhD, William H. Morrison, MD, Debra A. Ruzensky, RD, David I. Rosenthal, MD; Radiation Oncology Unit, Chulabhorn Hospital; Department of Radiation Oncology, UT MD Anderson Cancer Center; Department of Radiation Oncology, Netherlands Cancer Institute; UT Medical School, Houston

BACKGROUND: Major weight loss before or during head and neck squamous cell cancer (HNSCC) treatment is common. We investigated the impact of weight loss, cachexia, and sarcopenia-the isolated loss of lean body mass-as determined by a novel method using routine staging positron emission tomography-computed tomography (PET-CT) scans on cancer treatment outcomes.

METHODS: Biometric data were collected on consecutive patients with American Joint Committee on Cancer (AJCC) stage IVA–IVB HNSCC treated with radiation therapy (RT) with or without concurrent chemotherapy between 2003 and 2013 and who had paired pre- and posttreatment PET-CTs. Cachexia was defined as > 5% weight loss for < 6 months or body mass index (BMI) < 20 kg/m2 with 2% weight loss. Sarcopenia was defined by CT-measured L3 skeletal muscle index of < 52.4 cm2/m2 for men and < 38.5 cm2/m2 for women, as described by Prado et al (2013). We evaluated the effect of pre- and post-RT sarcopenia on outcomes. Survival curves were constructed using the Kaplan-Meier technique. Log-rank test was used to compare outcomes. Univariate and multivariate overall survival (OS) modeling was performed using parametric survival fitting to allow intramodel comparison using corrected Bayesian information criteria (BIC).

RESULTS: A total of 175 patients were identified, and the median follow-up was 67.9 months. We detected sarcopenia in 65 patients (37.1%) prior to RT. Sarcopenia was identified in an additional 47 of 110 patients (42.7%) on the post-RT scan. All patients who developed sarcopenia on the post-RT study had decreased locoregional control (LRC), OS, and disease-specific survival (DSS) (P < .05 for all). Sarcopenia that was identified on the pre-RT PET-CT showed the same patterns but only for nonoperated patients, where the 5-year OS was decreased from 66.7 ± 1.0% to 17.8 ± 10.2% (P < .001). Posttreatment sarcopenia was more substantive in competing multivariate models of mortality risk than simple weight and BMI-based cachexia metrics (ΔBIC ≥ 12.9).

DISCUSSION: We confirm that analysis of routine CT scans for sarcopenia can predict outcomes for HNSCC patients. Pre-RT sarcopenia is associated with more poor outcomes for nonoperated patients and post-RT sarcopenia for all HNSCC patients. Post-RT sarcopenia, as measured by routine CT, outperformed simple weight loss and BMI-derived cachexia metrics, because loss of lean muscle mass can occur independently of BMI status. These findings suggest the potential benefit for investigating intervention with aggressive nutritional and physiatric methods to prevent sarcopenia during RT and to study how these interventions might affect outcomes in nonoperated, pre-RT sarcopenia patients.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content